U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07186296) titled 'EXoPERT EMERALD Clinical Study' on Aug. 29.
Brief Summary: Invitro diagnostic test for multiple cancer diagnosis for patients with early-stage cancers by analyzing surface-enhanced Ramen spectroscopy (SERS) profiles of extracellular vesicles (EV) using artificial intelligence.
Study Start Date: May 09
Study Type: OBSERVATIONAL
Condition:
Breast Cancer
Colon Cancer
Pancreatic Cancer
Ovarian Cancer
Lung Cancer
Intervention:
DIAGNOSTIC_TEST: EXoPred
Performing invitro Diagnostics with devices developed by EXoPERT.
Recruitment Status: RECRUITING
Sponsor: EXoPERT
Published by HT Digital Content Services with permission from He...